Journey Medical
DERM
17 hedge funds and large institutions have $3.47M invested in Journey Medical in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.74% less ownership
Funds ownership: 16.19% → 15.45% (-0.74%)
15% less funds holding
Funds holding: 20 → 17 (-3)
36% less capital inflows, than outflows
Capital inflows: $511K | Capital outflows: $793K
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$447K |
| 2 |
Perkins Capital Management
Wayzata,
Minnesota
|
+$33.3K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$5.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.7K |
| 5 |
BlackRock
New York
|
+$372 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$638K |
| 2 |
Neuberger Berman Group
New York
|
-$57.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$54K |
| 4 |
Focus Partners Advisor Solutions
Saint Louis,
Missouri
|
-$25K |
| 5 |
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$10.6K |
DERM Hedge Fund Activity: Q4 2022 in Review
17 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q4 2022, worth a combined $3.47M — down 25% from $4.62M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of DERM and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $447K. The largest seller was Opaleye Management, exiting entirely with an estimated $638K sold.
- 17 institutional investors held Journey Medical (DERM) as of Q4 2022, down from 20 in Q3 2022.
- Funds reported $3.47M of Journey Medical stock for Q4 2022, down 25% quarter-over-quarter.
- 3 funds opened new Journey Medical positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Journey Medical buyer in Q4 2022 was Nantahala Capital Management, an estimated $447K added.
- The largest Journey Medical seller in Q4 2022 was Opaleye Management, an estimated $638K sold.
Based on aggregated 13F filings for Q4 2022.